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According to the Sepsis-3 definitions, sepsis is nowadays defined as a life-threatening organ dysfunction due to the dysregulated host response to an infection \[[@CR1]\]. The mainstay of management relies on the prompt recognition of the septic patient, since final outcome much depends on the time of start of antimicrobials. More precisely, a retrospective survey in 2713 patients with septic shock showed that final survival was 79.1% for those starting adequate antimicrobial therapy within the first 1 h from the advent of hypotension; the chances for survival were decreasing by 7.6% for every hour of delay of the start of antimicrobial therapy \[[@CR2]\]. However, the efficacy of an early start of antimicrobials relies on the susceptibility of empirically administered antimicrobials on the implicated pathogens. Until now, microbiology techniques cannot provide information on the pathogen and susceptibility pattern in less than an hour. Even more, the likelihood of sepsis due to infection by resistant isolates which is emerging globally is generating the question as to what antimicrobial should be administered as early treatment. Although information coming from the epidemiology of the patient, such as recent hospitalization, intake of antibiotics in the last 3 months and residence in a long-term care facility, may help in assessing the risk of infection of the patient by multidrug-resistant isolates \[[@CR3]\], there are many patients with infections acquired inside the intensive care unit caused by extensive drug-resistant or pandrug-resistant isolates.

This leads to two unmet medical needs: (1) early recognition of the septic patient, and (2) early recognition of the pathogen and the evaluation of its susceptibilities to antimicrobials. Raman4Clinics is a consortium of experts funded by the COST European initiative aimed at education towards the development of the Raman photonic technology for medical diagnostics. Part of this initiative is dedicated to the diagnostics of severe infections. This initiative also interacts with the FrameWork 7-funded European consortium, HemoSpec. The goal of HemoSpec is to develop a device that integrates information coming from the measurement of serum biomarkers and Raman microscopy of circulating white blood cells for the early diagnosis of sepsis.

Raman4Clinics organized a session during the Conference of the Hellenic Sepsis Study Group on June 18, 2017, at Kalamata, Greece. The session hosted a presentation for the conduct of the INTELLIGENCE-1 which that is a prospective study running at five sites in Greece on the diagnostic performance of the HemoSpec device for sepsis (ClinicalTrials.gov NCT03306186). The session also hosted three presentations which are also published in this supplement of the journal. These presentations are representative of the rationale of the developing collaboration in Rama4Clinics, i.e. the interaction between clinicians and biologists. To this end, one presentation was dedicated to the use of Raman microscopy for the recognition of the diversity of fungi, and two presentations were on the determinants of the endothelial dysfunction of the host in sepsis.
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